ライフサイエンスコーパス: PET scan

1 y)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide PET scan.

2 dose of (18)F-FDG followed by a dual-imaging PET scan.

3 hologic (astrocytosis) aspects from a single PET scan.

4 dication of a clinically justified (18)F-FDG PET scan.

5 received a 90-min dynamic (S)-(18)F-THK5117 PET scan.

6 83 and micro-CT scan, but not with (18)F-FDG PET scan.

7 and additionally an experimental (11)C-PE2I PET scan.

8 ximab vedotin treatment, patients received a PET scan.

9 ity and underwent a second [(18)F]fallypride PET scan.

10 -FDG was injected, followed by a 3-h dynamic PET scan.

11 intravenously, followed by a 60-min dynamic PET scan.

12 er of visible and measurable lesions on each PET scan.

13 e time interval between baseline and the tau PET scan.

14 with unprecedented precision using data from PET scans.

15 h each undergoing three 90-min (11)C-HOMADAM PET scans.

16 iple organs on the CT scan and copied to the PET scans.

17 tching healthy controls received (11)C-PBR28 PET scans.

18 and therefore diagnostic accuracy of cardiac PET scans.

19 )Tc-based hepatobiliary scans, and (18)F-FDG PET scans.

20 ria or (for MP) by changes in (123)I-MIBG or PET scans.

21 ions can be identified on planar, SPECT, and PET scans.

22 s with negative results on bone or (18)F-NaF PET scans.

23 h, and FTD patients also underwent (18)F-FDG PET scans.

24 icobasal degeneration patients who underwent PET scans.

25 ons that were visible and measurable on both PET scans.

26 sessed by CT and perfusion by (13)N ((13)NN) PET scans.

27 and might be applied to clinical, whole-body PET scans.

28 seline amyloid positron emission tomography (PET) scan.

29 tion using tau positron emission tomography (PET) scans.

30 oxyglucose positron emission tomography (FDG-PET) scans.

31 oxyglucose positron emission tomography (FDG-PET) scans.

32 A subjects showed beta-amyloid deposition on PET scanning.

33 ived three cycles of ABVD and then underwent PET scanning.

34 ) were recruited, and 571 patients underwent PET scanning.

35 abeling an anti-ICOS antibody and performing PET scanning.

36 )C]carfentanil positron emission tomography (PET) scanning.

37 were collected, resulting in a total of 128 PET scans (1-7 d after injection from 36 patients: (89)Z

38 ic CT scan (80 kV, 165 mAs) and a subsequent PET scan (2 min per bed position).

39 Up to 3 PET scans (2 hours post infusion [p.i.] and days 2 and 5

40 PET scans (20-40 min after injection) were evaluated vis

41 PET scan (5 patients) or SPECT (2 patients) revealed par

42 11 of 18 positive baseline (11)C-methionine PET scans (61%) showing less than 25% (11)C-methionine-a

43 In total, 113 patients had an EOT PET scan: 63% negative and 37% positive with a 5-year TT

44 patients had a follow-up (11)C-(R)-rolipram PET scan 8 weeks after treatment with an SSRI.

45 patients had a follow-up (11)C-(R)-rolipram PET scan ~8 weeks after treatment with an SSRI.

46 Healthy controls also underwent PET scans according to the corresponding schedule of the

47 abolic RSN expression in cerebral blood flow PET scans acquired at rest and during task performance.

48 view, followed by a series of 13 whole-body PET scans acquired over a 90-min period.

49 f 27 cases (41%), results from the (18)F-FET PET scans added relevant clinical information, including

50 of each other (501 participants had a second PET scan after 2 years, including 150 participants with

51 subset of participants underwent a second MR-PET scan after a median interscan interval of 3.6 months

52 patients (>/=90%) achieved negative interim PET scans after 2 and 4 cycles of BV + AVD.

53 and wild-type control rats underwent dynamic PET scans after administration of (11)C-BMP intravenousl

54 hereafter referred to as simply florbetapir)-PET scan and at least 1 CSF beta-amyloid 1-42 (Abeta1-42

55 younger, more likely to have a positive PiB-PET scan and carry at least one apolipoprotein E varepsi

56 ers underwent a high-resolution [(18)F]FEPPA PET scan and MRI.

57 ers underwent a high-resolution [(18)F]FEPPA PET scan and MRI.

58 ealthy controls underwent a [(11)C]Ro15-4513 PET scan and MRI.

59 xenografts were detected by micro CT, (18)F-PET scan and NIR imaging scan.

60 antification is achieved by a 60-min dynamic PET scan and the use of either cerebellum or midbrain as

61 he patients could tolerate the procedures of PET scanning and RT.

62 urgh compound B (PIB) and (18)F-flortaucipir PET scans and a magnetization-prepared rapid gradient ec

63 ke value ratios (SUVRs) were calculated from PET scans and a mean global cortical SUVR was calculated

64 Data obtained from PET scans and biodistribution studies were extrapolated

65 (18)F-FET PET scans and ex vivo autoradiography were performed in

66 eline MRI, Pittsburgh compound B-PET and FDG-PET scans and neuropsychological evaluation.

67 ts with cocaine-use disorder (CUD) underwent PET scans and performed two types of cocaine self-admini

68 patients underwent dynamic (11)C-(R)PK11195 PET scans and perfusion MR imaging acquisition.

69 n 3 cohorts; all underwent dynamic (18)F-FDG PET scans and serial pharmacokinetic sampling at baselin

70 ncer patients underwent diagnostic (18)F-FDG PET scans and were tested for genetic mutations.

71 ncer patients underwent diagnostic (18)F-FDG PET scans and were tested for genetic mutations.

72 r, we utilized positron emission tomography (PET) scanning and the tracer (18)F-fluorodeoxyglucose (F

73 percent of patients had a positive (18)F-FLT PET scan, and 49% had (18)F-FDG PET-positive foci.

74 in epsilon4, concurrent fludeoxyglucose F 18 PET scan, and baseline cognitive status.

75 were perfused and sacrificed after the final PET scan, and radioactivity in dissected tissues was mea

76 he animals were followed-up with serial MRI, PET scans, and histology 6 months post-radiation.

77 d positive Tau positron emission tomography (PET) scans (area under the curve (AUC) = 0.87-0.91 for d

78 ts from group 2, who underwent a second PSMA PET scan as a follow-up, were evaluated to determine the

79 uoride positron emission tomography (18F-NaF PET) scans as target-to-background ratios (TBRs), a prom

80 ocols using (18)F-DCFPyL (n = 62, 269.8 MBq, PET scan at 120 min after injection) or (68)Ga-PSMA-HBED

81 ocols using (18)F-DCFPyL (n = 62, 269.8 MBq, PET scan at 120 min after injection) or (68)Ga-PSMA-HBED

82 nt at magnetic resonance imaging, a positive PET scan at baseline, or lack of improvement at repeat P

83 - 82 MBq of (18)F-FGln, followed by 2 static PET scans at 97 +/- 14 and 190 +/- 12 min after injectio

84 Patients underwent (89)Zr-bevacizumab PET scans at baseline and 2 and 6 wk after initiating ei

85 ic innervation) were calculated from dynamic PET scans at the location of BAT and WAT.

86 -tau217 discriminated abnormal vs normal tau-PET scans (AUC, 0.93 [95% CI, 0.91-0.96]) with significa

87 ry 1, 1997, and December 31, 2011, and had a PET scan available for current review.

88 thy male volunteers received [(11)C]CIMBI-36 PET scans before and 3 h after an oral dose of d-ampheta

89 anced solid tumors underwent (11)C-erlotinib PET scans before and after a 1,000-mg dose of elacridar.

90 PET scans before and after task performance indicated a

91 Rats were subjected to (11)C-PK11195 PET scans before SE; at 4 h after SE; at 1, 2, 5, 7, 14,

92 [(11)C]FLB457 positron emission tomography (PET) scans before and 3-hours after amphetamine administ

93 nteers (HV) underwent two [(11)C]carfentanil PET scans, before and after an oral administration of 0.

94 Static (18)F-PI-2620 PET scans between 45 and 75 min after injection provide

95 Static (18)F-PI-2620 PET scans between 45-75min p.i.

96 At the end of the PET scans, brains were harvested for immunohistochemical

97 At the end of the PET scans, brains were harvested for immunohistochemical

98 rwent PET/CT scanning with a 120-min dynamic PET scan centered on the pancreas.

99 A positron emission tomography (PET) scan confirmed the lung lesion and the mediastinal

100 ved a negative positron emission tomography (PET) scan (Deauville score of 1-3) received 30 Gy ISRT.

101 In RAPID, a positive PET scan did not carry uniform prognostic weight; only a

102 n a series of pregnant women who underwent a PET scan during a clinical workup for malignancies.

103 tative stability assessment for simultaneous PET scanning during functional MRI studies was performed

104 In addition to an (18)F-FDG PET scan, each patient underwent a 45-min (18)F-fluoromi

105 onsidered for quantitative (18)F-florbetaben PET scans, especially in assessing patients with brain a

106 After PET scanning, Evans blue dye (EBD) was injected into ani

107 all, 15 of 549 (2.7%) patients with baseline PET scans experienced biopsy-confirmed HT (median follow

108 Patients achieving complete response (CR) on PET scan following cycle 2 of ABVD (PET2) continued 4 ad

109 In patients with prior NaF PET scans for comparison, continuing current therapy was

110 with 136 18-kDa translocator protein (TSPO) PET scans for microglial activation.

111 ere quantified in 60 clinical (68)Ga-PSMA-11 PET scans for recurrent disease as well as the 9 primary

112 tinely used in positron emission tomography (PET) scans for cancer diagnosis, staging, and monitoring

113 w SPECT/CT scans, and whole-body (124)I-MIBG PET scans found 25, 32, and 87 total lesions, respective

114 cer patients who underwent staging (18)F-FDG PET scans from 2002 to 2013 at the Peter MacCallum Cance

115 follow-up ( approximately 24 mo) florbetapir PET scans from 332 Abeta+ and Abeta- subjects participat

116 nding on the quantification of (18)F-DPA-714 PET scans from a cohort of healthy subjects.

117 Restaging (18)F-FDG PET scans had a high impact in 24 of 53 cases (45%) and

118 with a shorter OS than a negative (18)F-FDG PET scan (hazard ratio: 3.8; 95% CI: 2.4-5.9; P < 0.001)

119 enty patients (77.8%) showed a positive PSMA-PET scan, identifying a total of 287 lesions: 37 prostat

120 Using PET scan in humans, we have recently found that 5-HT 1A

121 lations were based on a whole-body (18)F-FDG PET scan in which differently sized spheres were placed

122 r (11)C-labeled ligands, allowing for serial PET scanning in a single subject.

123 udies aimed at assessing the role of interim PET scanning in HL, were retrospectively included.

124 ale subjects each had two 120-min [11C]PBR28 PET scans in 1 d, before and after an LPS challenge.

125 ined baseline 6-[(18)F]fluoro-L-DOPA (FDOPA)-PET scans in 15 nonsmokers and 30 nicotine-dependent smo

126 and markers since 1987-1989 with florbetapir PET scans in 2011-2013.

127 We obtained 62 cardiac (11)C-HED PET scans in 39 patients (30 men and 9 women; mean age +

128 subjects underwent 10 consecutive whole-body PET scans in approximately 77 min.

129 m (68)Ga-DOTA-E-[c(RGDfK)]2 using whole-body PET scans in humans.

130 PET scans in rhesus macaques were acquired for 2 h with

131 PET scans in rhesus monkeys were obtained on a small-ani

132 C]-carfentanil positron emission tomography (PET) scans in 19 schizophrenia patients and 20 age-match

133 epileptiform discharges had an [(18)F]GE-179 PET scan, in a cross-sectional study.

134 disease (AD) subjects underwent two dynamic PET scans including arterial sampling.

135 er disease (AD) subjects underwent 2 dynamic PET scans, including arterial sampling.

136 C-RO6931643, and (11)C-RO6924963 to baboons, PET scans indicated good brain entry, rapid washout, and

137 diation burden of a diagnostic (18)F-FAPI-74 PET scan is even lower than that of PET scans with (18)F

138 We confirmed that (18)F-FDG PET scanning is a reliable tool for BMI assessment in HL

139 fication of subjects on the basis of amyloid PET scans is increasingly being used in research studies

140 Vascular uptake on PET scans is seen in some patients.

141 (89)Zr-bevacizumab accumulation assessed by PET scanning may help in the selection of patients with

142 ed prostate-specific membrane antigen (PSMA) PET scans may be used to monitor treatment response in p

143 In conclusion, (18)F-GE180 PET scans may be useful for longitudinal monitoring of n

144 valuation with positron emission tomography (PET) scan may improve selection of patients who need red

145 as remote from the tumor on the preoperative PET scan (n = 6) (2.92 +/- 1.24 vs. 1.62 +/- 0.75; P < 0

146 For those with Deauville (D)-scored PET scans (n = 103), the 5-year TTP for PET-negative cas

147 A small-animal PET scan of a rhesus monkey revealed moderate initial br

148 thy tissues were estimated on (68)Ga-DOTATOC PET scans of 11 meningioma patients and 12 HGG patients.

149 (18)F-FDG PET scans of 132 children and adolescents (age, 1-20 y)

150 ase dementia patients, received flortaucipir PET scans of 20 min in duration beginning 80 min after i

151 Sixty-nine (18)F-FET PET scans of 48 children and adolescents (median age, 13

152 thods: We analyzed 523 cross-sectional Abeta PET scans of 5 different Abeta mouse models (APP/PS1, PS

153 Serial whole-body PET scans of 5 subjects with recently diagnosed thyroid

154 Methods: (18)F-FDG PET scans of 544 MCI patients were obtained from the Alz

155 e-activity curves were assessed with dynamic PET scans of 6 healthy human volunteers.

156 Dynamic (11)C-phenytoin PET scans of 6 healthy volunteers with arterial sampling

157 meters were estimated from dynamic (18)F-FDG PET scans of breast cancer patients and used to simulate

158 e evaluated pre- and postoperative (18)F-FET PET scans of glioma patients with particular emphasis on

159 PET scans of individuals injected with 2-chloro-2'-deoxy

160 We further show through brain PET scans of monkeys injected with radiolabeled recombin

161 Papio anubis baboons underwent PET scans of the brain after intravenous injection of (1

162 PET scans of the mouse brain are usually performed with

163 Methods: Dynamic PET scans of up to 150 min were performed on 4 cognitive

164 Small-animal PET scans of Wistar rats revealed moderate initial brain

165 al Status (BSMSS), an MRI and an [(11)C]EKAP PET scan on the High Resolution Research Tomograph.

166 We performed PET scans on mRCC patients with (89)Zr-bevacizumab, a VE

167 tobacco smokers had one set of [(11)C]FLB457 PET scans on the same day, one before and one at 2.5-3 h

168 [(11)C]ABP688 positron emission tomography (PET) scans on the same day-before and during intravenous

169 cipants who underwent two [(11)C]carfentanil PET scans, one before and one 3 h following a 0.5 mg/kg

170 be SUVAUC derived from 2 consecutive static PET scans, one centered on a large blood-pool structure

171 70 d underwent (11)C-metoclopramide baseline PET scans or scans after intraperitoneal treatment with

172 days underwent (11)C-metoclopramide baseline PET scans or scans after intraperitoneal treatment with

173 X, 12 healthy volunteers underwent a dynamic PET scan over 120 min.

174 release, we collected two [(11)C]raclopride PET scans per participant.

175 itative) and DeltaSUV(max) scales to interim PET scans performed after 2 cycles of chemotherapy.

176 er radiomic features extracted from baseline PET scans predicted relapsed or refractory disease statu

177 Four different PET scans processing pipelines from 2 different laborato

178 Results: For 3,774 sequential rest-stress PET scans, regional, artery-specific, severely reduced c

179 % (27 or 29) of patients achieved a negative PET scan, respectively.

180 Positron emission tomography (PET) scan response at month 6 was used as the main evalu

181 Our analyses demonstrated that NaF PET scan results are highly associated with subsequent h

182 In vivo PET scans revealed an overt age-dependent elevation in w

183 Results: Visual analysis of (18)F-FET PET scans revealed complete resection in 16 of 43 patien

184 Participants underwent a dynamic PET scanning session with bolus injection of [(11)C]DAA1

185 eek prior to a positron emission tomography (PET) scan session, during which the subject's head was s

186 ied as AD dementia but having negative Abeta PET scans show little increase but plasma p-tau181 is in

187 of the CSF Abeta1-42 samples and florbetapir-PET scans showed a nonlinear association (R2 = 0.48-0.66

188 f levels; and different pipelines to process PET scans showed correlated but not identical results.

189 resulting full width at half maximum of the PET scans showed the spatial resolution improved by up t

190 ET/CT imaging was obtained with 2 successive PET scans starting at 2 h after injection.

191 showed a high (68)Ga-PSMA-11 accumulation on PET scans (SUV(max) 23.5 +/- 5.2).

192 , 20 drug-free patients) underwent a dynamic PET scan to measure [(11)C] MePPEP distribution volume (

193 thermore, they also underwent an [(18)F]DOPA PET scan to quantify striatal dopamine synthesis capacit

194 n the satiated state) and blood draws during PET scanning to determine TSPO affinity genotype and pla

195 disorder were followed up for 12 weeks after PET scanning to document relapse and relate it to V(T).

196 and 10 controls also underwent [(11)C]NNC112 PET scans to measure dopamine D1-type receptor availabil

197 two independent cohorts underwent (18)F-DOPA PET scans to measure dopamine synthesis capacity (indexe

198 rodeoxyglucose positron emission tomography (PET) scan to guide consolidative RT.

199 so completed a positron emission tomography (PET) scan to quantify DRN 5-HT1A availability using [(11

200 The PET scan took place 2 hr after the induction of acute ps

201 Longitudinal PET scans unveiled a lasting and prominent (89)Zr-Df-ALT

202 independently rated the quality of each PSMA-PET scan using a 3-point Likert-type scale.

203 ment the region corresponding to BM from the PET scan using algorithms developed in-house, allowing f

204 The quality of the corrected PET scan using our pseudo-CT volume is comparable to hav

205 Participants underwent a PET scan using the TSPO-specific radioligand [(11)C](R)-

206 patients with MDD (HDRS-24 = 24.8) underwent PET scanning using (11)C-DASB.

207 phosphate to induce AAA and underwent weekly PET scans using (64)Cu-NOTA-TRC105-Fab.

208 reward-related questionnaires and underwent PET scans using the D2R-selective and nondisplaceable ra

209 of [(11)C]IMA107 were generated from dynamic PET scans using the simplified reference tissue model wi

210 nce of a larger dynamic range of florbetapir-PET scan values in the higher range compared with the CS

211 (89)Zr-bevacizumab PET scans visualized 125 evaluable tumor lesions in 22 p

212 risk of hospice claims within 180 d of a NaF PET scan was 2.0-7.5 times higher for patients with evid

213 A dynamic PET scan was acquired for 90 s with the brain in the fie

214 fter hPBMC inoculation, and a 60-min dynamic PET scan was acquired, followed by ex vivo biodistributi

215 le cohort revealed that a positive (18)F-FDG PET scan was associated with a shorter OS than a negativ

216 Each PET scan was interpreted by three independent masked rea

217 In 4 patients, an additional PET scan was obtained on day 2 after injection.

218 A PET scan was performed after two initial cycles of doxor

219 An additional PET scan was performed to calculate test-retest reproduc

220 G2 patients (n = 140), a positive (18)F-FDG PET scan was the only identifier of high risk for death

221 eded, and no treatment adaptation on interim PET scanning was allowed.

222 The number of lesions on both PET scans was counted and grouped according to organs or

223 es without prior local therapy and (18)F-FET PET scanning were retrospectively identified in 2 center

224 es without prior local therapy and (18)F-FET PET scanning were retrospectively identified in 2 center

225 PET scans were acquired 1 h after injection of 202 MBq (

226 PET scans were acquired 60 min after administration of 1

227 Methods: In 10 patients with lung cancer, PET scans were acquired at 10 min, 1 h, and 3 h after ad

228 (18)F-FDG PET scans were acquired at 3 and 7 d after TAC, under ke

229 [(18)F]FDG-PET scans were acquired at baseline, week 1, and week 8.

230 [(18)F]FPEB PET scans were acquired first during early abstinence (6

231 was injected via the tail vein, and dynamic PET scans were acquired for 90 min, followed by gamma-co

232 (18)F-FDG PET scans were acquired in 8 healthy macaques and 8 maca

233 Pre- and posttreatment PET scans were acquired in protocols compliant with the

234 Non-invasive PET scans were acquired in tumor-bearing mice injected w

235 ion of 37 MBq (5 mg) of (89)Zr-fresolimumab, PET scans were acquired on day 2 or day 4 after tracer i

236 In each subject, 4 sequential PET scans were acquired to estimate whole-body and indiv

237 Methods: Dynamic (18)F-flutemetamol PET scans were acquired using a coffee-break protocol (a

238 )methyl)-N-(6-phenoxy-3-pyridinyl)acetamide) PET scans were acquired with arterial blood sampling to

239 PET scans were assessed at 6 time points, up to 110 min

240 PET scans were conducted in 3 separate sessions, and sub

241 ne imaging, 26 of 38 (68%) bone or (18)F-NaF PET scans were congruent with (18)F-DCFPyL PET, whereas

242 PET scans were done under conditions of suppressed and s

243 Preoperative MR imaging and (68)Ga-DOTATATE PET scans were fused and used for a spatially precise ne

244 PET scans were fused with routine MRI of the central ner

245 call echo MRI, tau-PET (AV-1451) and amyloid-PET scans were identified.

246 FDOPA and [(11)C]SB217045) and more than 400 PET scans were investigated to assess the applicability

247 During each imaging session, 9 whole-body PET scans were obtained at 5, 10, 20, 30, 40, 50, 60, 12

248 Seventy (18)F-FDG PET scans were obtained for 63 GIST patients to evaluate

249 Forty-two (11)C-dLop PET scans were obtained from 37 healthy volunteers.

250 (18)F-FDG and (18)F-FLT PET scans were obtained in 17 patients with FL and 9 pat

251 In the first step, basic PET scans were obtained in 4 different preclinical imagi

252 Two (test-retest) dynamic (11)C-laniquidar PET scans were obtained in 8 healthy subjects.

253 Both dynamic and static PET scans were obtained in a mouse inflammation model in

254 (11)C-DED, (11)C-PiB, and (18)F-FDG dynamic PET scans were obtained in age-matched groups comprising

255 (18)F-fluoroestradiol PET and (18)F-FDG PET scans were performed at baseline, week 2, and week 8

256 -sorafenib and perfusion (15)O-H(2)O dynamic PET scans were performed before and after 2 wk of sorafe

257 Thirty-minute dynamic PET scans were performed concurrently with a rapid intra

258 Two [(11)C]ABP688 PET scans were performed in 10 healthy nonsmoking human

259 ods: (11)C-(R)-rolipram whole-body and brain PET scans were performed on 6 individuals with MAS (3 fo

260 One-hour dynamic PET scans were performed on nude mice bearing subcutaneo

261 an volunteers (34 +/- 13 years old); the two PET scans were performed on the same day-before (scan 1)

262 Results: Overall, 104 of 200 (52%) PSMA-PET scans were positive for PCa-related findings.

263 Coronary (68)Ga-DOTATATE PET scans were readable in all patients.

264 Quantitative whole-body PET scans were recorded to measure the kinetics for 14 o

265 (18)F-FDG PET scans were selected and grouped according to 3 prepa

266 In addition, the (18)F-FDG PET scans were visually assessed to determine whether th

267 ven whole-body positron emission tomography (PET) scans were performed 5, 10, 20, 30, 45, 150, and 24

268 -(R)-rolipram positron emission tomographic (PET) scans were performed in 44 unmedicated patients dur

269 ve microglia in-vivo is often performed with PET scanning whose resolution, cost, and availability pr

270 Within 3 wk, a second PET scan with (18)F-PSMA-1007 was performed (PET-2).

271 whom had undergone 3 T MRI scan, 985 amyloid PET scan with 11C-Pittsburgh compound B (PIB) and MRI, a

272 A dynamic PET scan with a field of view covering target tissues of

273 A 90-min dynamic PET scan with arterial blood sampling and metabolite ana

274 Methods: A 90-min dynamic PET scan with arterial blood sampling and metabolite ana

275 fter tumor inoculation, a dynamic (18)F-FHNP PET scan with arterial blood sampling was acquired from

276 , a dynamic (11)C-PBR28 or (R)-(11)C-PK11195 PET scan with arterial blood sampling was obtained.

277 After a baseline PET scan with the D2/3 ligand [(18)F]fallypride, rats re

278 MRI scan and on a separate visit completed a PET scan with the high affinity D2R tracer [18 F]fallypr

279 underwent 3 T MRI and a 120-min 11C-BU99008 PET scan with volume of distribution (VT) estimated usin

280 complex logistics of combining a whole-body PET scan with whole-body or organ-specific MR imaging.

281 tor protein (TSPO) binding status, underwent PET scanning with TSPO radioligands ((11)C-PBR28 or (18)

282 eless, the results confirm the usefulness of PET scans with (11)C-(R)-rolipram to indirectly measure

283 Methods: Healthy men underwent 2 consecutive PET scans with (11)C-erlotinib: a baseline scan and a se

284 -FAPI-74 PET scan is even lower than that of PET scans with (18)F-FDG and other (18)F tracers; (68)Ga

285 Dynamic PET scans with (18)F-FETrp and (11)C-AMT were obtained f

286 ed-affinity binders) underwent (18)F-DPA-714 PET scans with arterial blood sampling and metabolite an

287 men and 5 women) underwent 2 separate 90-min PET scans with arterial input function and plasma free f

288 subsequent dynamic (15)O-H2O and (18)F-FAZA PET scans with arterial sampling.

289 althy subjects underwent 120-min test-retest PET scans with both (11)C-EKAP and (11)C-FEKAP.

290 Ninety-minute dynamic (18)F-DPA-714 PET scans with full arterial sampling from 6 healthy sub

291 Rats and mice underwent 4 PET scans with increasing doses of the unlabeled ligand

292 g data employed in the study consisted of 26 PET scans with lesions in the lung being created through

293 We performed PET scans with the ABCB1 substrate (R)-(11)C-verapamil o

294 Methods: We performed PET scans with the ABCB1 substrate (R)-(11)C-verapamil o

295 g (MRI) scans, positron emission tomography (PET) scans with carbon 11-labeled Pittsburgh Compound B

296 eers underwent positron emission tomography (PET) scans with the 5-HT2AR agonist radioligand [(11)C]C

297 ects underwent positron emission tomography (PET) scans with two different radiotracers at baseline p

298 One hundred patients were PET-scanned with both (18)F-FLT and (18)F-FDG within the

299 underwent 2 consecutive (11)C-metoclopramide PET scans without and with ABCB1 inhibition using cyclos

300 In the 23 paired PET scans, worsening cardiac denervation (global diff-SE